Cargando…
GM1 Oligosaccharide Efficacy in Parkinson’s Disease: Protection against MPTP
Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson’s disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however, the physical and chemical properties of GM1 (i.e...
Autores principales: | Fazzari, Maria, Lunghi, Giulia, Henriques, Alexandre, Callizot, Noëlle, Ciampa, Maria Grazia, Mauri, Laura, Prioni, Simona, Carsana, Emma Veronica, Loberto, Nicoletta, Aureli, Massimo, Mari, Luigi, Sonnino, Sandro, Chiricozzi, Elena, Di Biase, Erika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216367/ https://www.ncbi.nlm.nih.gov/pubmed/37238977 http://dx.doi.org/10.3390/biomedicines11051305 |
Ejemplares similares
-
Turning the spotlight on the oligosaccharide chain of GM1 ganglioside
por: Chiricozzi, Elena, et al.
Publicado: (2021) -
GM1 Oligosaccharide Crosses the Human Blood–Brain Barrier In Vitro by a Paracellular Route
por: Di Biase, Erika, et al.
Publicado: (2020) -
Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1(+/−) mouse model
por: Chiricozzi, Elena, et al.
Publicado: (2019) -
Modulation of calcium signaling depends on the oligosaccharide of GM1 in Neuro2a mouse neuroblastoma cells
por: Lunghi, Giulia, et al.
Publicado: (2020) -
Novel insights on GM1 and Parkinson's disease: A critical review
por: Fazzari, Maria, et al.
Publicado: (2022)